Annual EBITDA
-$24.73 M
-$4.33 M-21.25%
December 31, 2023
Summary
- As of February 8, 2025, ONCY annual EBITDA is -$24.73 million, with the most recent change of -$4.33 million (-21.25%) on December 31, 2023.
- During the last 3 years, ONCY annual EBITDA has fallen by -$6.06 million (-32.45%).
- ONCY annual EBITDA is now -6281.19% below its all-time high of -$387.50 thousand, reached on December 31, 1999.
Performance
ONCY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$7.18 M
-$1.39 M-24.03%
September 30, 2024
Summary
- As of February 8, 2025, ONCY quarterly EBITDA is -$7.18 million, with the most recent change of -$1.39 million (-24.03%) on September 30, 2024.
- Over the past year, ONCY quarterly EBITDA has increased by +$978.60 thousand (+12.00%).
- ONCY quarterly EBITDA is now -2457.73% below its all-time high of -$280.60 thousand, reached on March 31, 2000.
Performance
ONCY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$25.86 M
+$978.60 K+3.65%
September 30, 2024
Summary
- As of February 8, 2025, ONCY TTM EBITDA is -$25.86 million, with the most recent change of +$978.60 thousand (+3.65%) on September 30, 2024.
- Over the past year, ONCY TTM EBITDA has dropped by -$1.35 million (-5.52%).
- ONCY TTM EBITDA is now -9114.18% below its all-time high of -$280.60 thousand, reached on March 31, 2000.
Performance
ONCY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ONCY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.3% | +12.0% | -5.5% |
| 3 y3 years | -32.5% | -15.9% | -27.3% |
| 5 y5 years | -86.5% | -15.9% | -27.3% |
ONCY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.3% | at low | -57.2% | +12.0% | -29.5% | +3.6% |
| 5 y | 5-year | -65.0% | at low | -83.1% | +12.0% | -72.5% | +3.6% |
| alltime | all time | -6281.2% | +32.4% | -2457.7% | +37.3% | -9114.2% | +34.4% |
Oncolytics Biotech EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.18 M(+24.0%) | -$25.86 M(-3.6%) |
| Jun 2024 | - | -$5.79 M(-10.6%) | -$26.83 M(+2.0%) |
| Mar 2024 | - | -$6.47 M(+0.8%) | -$26.30 M(+6.3%) |
| Dec 2023 | -$24.73 M(+21.3%) | -$6.42 M(-21.3%) | -$24.73 M(+0.9%) |
| Sep 2023 | - | -$8.16 M(+55.3%) | -$24.50 M(+17.2%) |
| Jun 2023 | - | -$5.25 M(+7.1%) | -$20.91 M(+2.9%) |
| Mar 2023 | - | -$4.91 M(-20.8%) | -$20.32 M(+0.0%) |
| Dec 2022 | -$20.39 M(-0.8%) | -$6.19 M(+35.6%) | -$20.31 M(+1.8%) |
| Sep 2022 | - | -$4.57 M(-1.9%) | -$19.96 M(-1.3%) |
| Jun 2022 | - | -$4.65 M(-5.0%) | -$20.21 M(-3.3%) |
| Mar 2022 | - | -$4.90 M(-16.0%) | -$20.90 M(+1.6%) |
| Dec 2021 | -$20.57 M(+10.2%) | -$5.84 M(+21.1%) | -$20.57 M(-1.3%) |
| Sep 2021 | - | -$4.82 M(-9.8%) | -$20.84 M(+0.8%) |
| Jun 2021 | - | -$5.34 M(+16.9%) | -$20.68 M(+7.4%) |
| Mar 2021 | - | -$4.57 M(-25.2%) | -$19.26 M(+2.9%) |
| Dec 2020 | -$18.67 M(+24.6%) | -$6.11 M(+31.2%) | -$18.72 M(+5.8%) |
| Sep 2020 | - | -$4.66 M(+18.8%) | -$17.70 M(+13.5%) |
| Jun 2020 | - | -$3.92 M(-2.8%) | -$15.60 M(+0.7%) |
| Mar 2020 | - | -$4.03 M(-20.7%) | -$15.48 M(+3.3%) |
| Dec 2019 | -$14.99 M(+13.1%) | -$5.09 M(+98.8%) | -$14.99 M(+6.8%) |
| Sep 2019 | - | -$2.56 M(-32.8%) | -$14.03 M(-0.1%) |
| Jun 2019 | - | -$3.81 M(+7.6%) | -$14.06 M(+7.4%) |
| Mar 2019 | - | -$3.54 M(-14.4%) | -$13.09 M(-1.3%) |
| Dec 2018 | -$13.26 M(+10.7%) | -$4.13 M(+60.3%) | -$13.25 M(+3.9%) |
| Sep 2018 | - | -$2.58 M(-9.2%) | -$12.75 M(+1.4%) |
| Jun 2018 | - | -$2.84 M(-23.4%) | -$12.58 M(-3.0%) |
| Mar 2018 | - | -$3.70 M(+2.0%) | -$12.96 M(+8.6%) |
| Dec 2017 | -$11.97 M(+4.8%) | -$3.63 M(+50.9%) | -$11.94 M(-2.2%) |
| Sep 2017 | - | -$2.41 M(-25.4%) | -$12.20 M(-1.1%) |
| Jun 2017 | - | -$3.22 M(+20.5%) | -$12.34 M(+11.1%) |
| Mar 2017 | - | -$2.68 M(-31.3%) | -$11.11 M(-2.3%) |
| Dec 2016 | -$11.43 M(+6.2%) | -$3.90 M(+53.1%) | -$11.38 M(+12.7%) |
| Sep 2016 | - | -$2.55 M(+27.6%) | -$10.10 M(+3.9%) |
| Jun 2016 | - | -$2.00 M(-32.2%) | -$9.72 M(-10.5%) |
| Mar 2016 | - | -$2.94 M(+12.7%) | -$10.85 M(+0.6%) |
| Dec 2015 | -$10.76 M(-36.3%) | -$2.61 M(+20.5%) | -$10.79 M(-6.1%) |
| Sep 2015 | - | -$2.17 M(-30.8%) | -$11.49 M(-15.4%) |
| Jun 2015 | - | -$3.13 M(+8.8%) | -$13.58 M(-8.1%) |
| Mar 2015 | - | -$2.88 M(-13.1%) | -$14.78 M(-12.6%) |
| Dec 2014 | -$16.90 M(-26.8%) | -$3.31 M(-22.2%) | -$16.92 M(-11.7%) |
| Sep 2014 | - | -$4.26 M(-1.7%) | -$19.16 M(-8.1%) |
| Jun 2014 | - | -$4.33 M(-13.6%) | -$20.85 M(-3.0%) |
| Mar 2014 | - | -$5.02 M(-9.6%) | -$21.50 M(-6.9%) |
| Dec 2013 | -$23.08 M(-36.9%) | -$5.55 M(-6.7%) | -$23.09 M(-11.6%) |
| Sep 2013 | - | -$5.95 M(+19.4%) | -$26.12 M(-11.4%) |
| Jun 2013 | - | -$4.98 M(-24.6%) | -$29.48 M(-14.9%) |
| Mar 2013 | - | -$6.61 M(-23.0%) | -$34.64 M(-5.3%) |
| Dec 2012 | -$36.59 M | -$8.58 M(-7.9%) | -$36.57 M(-7.3%) |
| Sep 2012 | - | -$9.32 M(-8.2%) | -$39.44 M(+7.8%) |
| Jun 2012 | - | -$10.15 M(+18.9%) | -$36.57 M(+10.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$8.54 M(-25.4%) | -$33.16 M(+15.3%) |
| Dec 2011 | -$28.95 M(+50.6%) | -$11.44 M(+77.4%) | -$28.77 M(+16.5%) |
| Sep 2011 | - | -$6.45 M(-4.3%) | -$24.69 M(+11.8%) |
| Jun 2011 | - | -$6.74 M(+62.8%) | -$22.09 M(+12.7%) |
| Mar 2011 | - | -$4.14 M(-43.8%) | -$19.60 M(+1.6%) |
| Dec 2010 | -$19.22 M(+36.5%) | -$7.36 M(+91.1%) | -$19.30 M(+14.4%) |
| Sep 2010 | - | -$3.85 M(-9.3%) | -$16.87 M(+9.1%) |
| Jun 2010 | - | -$4.25 M(+10.7%) | -$15.46 M(+4.1%) |
| Mar 2010 | - | -$3.84 M(-22.2%) | -$14.85 M(+5.1%) |
| Dec 2009 | -$14.08 M(-15.3%) | -$4.93 M(+101.8%) | -$14.12 M(+8.0%) |
| Sep 2009 | - | -$2.44 M(-32.8%) | -$13.08 M(-10.5%) |
| Jun 2009 | - | -$3.64 M(+16.8%) | -$14.61 M(-10.4%) |
| Mar 2009 | - | -$3.11 M(-20.0%) | -$16.31 M(-0.6%) |
| Dec 2008 | -$16.63 M(+12.2%) | -$3.89 M(-2.1%) | -$16.41 M(-3.0%) |
| Sep 2008 | - | -$3.97 M(-25.5%) | -$16.92 M(+5.5%) |
| Jun 2008 | - | -$5.33 M(+65.9%) | -$16.03 M(+11.0%) |
| Mar 2008 | - | -$3.21 M(-27.0%) | -$14.44 M(-2.2%) |
| Dec 2007 | -$14.82 M(+15.4%) | -$4.40 M(+42.7%) | -$14.77 M(-4.7%) |
| Sep 2007 | - | -$3.08 M(-17.6%) | -$15.50 M(+1.6%) |
| Jun 2007 | - | -$3.74 M(+5.8%) | -$15.25 M(+9.2%) |
| Mar 2007 | - | -$3.54 M(-31.1%) | -$13.97 M(+8.8%) |
| Dec 2006 | -$12.84 M(+24.9%) | -$5.13 M(+80.7%) | -$12.83 M(+11.7%) |
| Sep 2006 | - | -$2.84 M(+15.8%) | -$11.49 M(+1.6%) |
| Jun 2006 | - | -$2.45 M(+2.0%) | -$11.30 M(+2.9%) |
| Mar 2006 | - | -$2.41 M(-36.4%) | -$10.99 M(+6.3%) |
| Dec 2005 | -$10.29 M(+6.2%) | -$3.78 M(+42.3%) | -$10.34 M(+21.4%) |
| Sep 2005 | - | -$2.66 M(+24.4%) | -$8.51 M(+2.1%) |
| Jun 2005 | - | -$2.14 M(+21.6%) | -$8.34 M(+0.1%) |
| Mar 2005 | - | -$1.76 M(-10.3%) | -$8.33 M(-2.0%) |
| Dec 2004 | -$9.69 M(+127.4%) | -$1.96 M(-21.1%) | -$8.50 M(+8.0%) |
| Sep 2004 | - | -$2.48 M(+16.6%) | -$7.87 M(+19.6%) |
| Jun 2004 | - | -$2.13 M(+10.6%) | -$6.59 M(+17.8%) |
| Mar 2004 | - | -$1.93 M(+44.6%) | -$5.59 M(+30.0%) |
| Dec 2003 | -$4.26 M(+8.2%) | -$1.33 M(+11.3%) | -$4.30 M(+8.5%) |
| Sep 2003 | - | -$1.20 M(+5.2%) | -$3.96 M(-0.2%) |
| Jun 2003 | - | -$1.14 M(+79.3%) | -$3.97 M(+8.2%) |
| Mar 2003 | - | -$634.50 K(-36.2%) | -$3.67 M(-4.8%) |
| Dec 2002 | -$3.94 M(-8.7%) | -$994.10 K(-17.5%) | -$3.85 M(+0.3%) |
| Sep 2002 | - | -$1.20 M(+44.0%) | -$3.84 M(-9.9%) |
| Jun 2002 | - | -$837.00 K(+2.4%) | -$4.26 M(-2.5%) |
| Mar 2002 | - | -$817.60 K(-16.7%) | -$4.37 M(+1.5%) |
| Dec 2001 | -$4.31 M(+44.1%) | -$981.60 K(-39.7%) | -$4.31 M(+12.8%) |
| Sep 2001 | - | -$1.63 M(+72.4%) | -$3.82 M(+13.4%) |
| Jun 2001 | - | -$944.40 K(+25.4%) | -$3.37 M(-2.7%) |
| Mar 2001 | - | -$753.20 K(+52.8%) | -$3.46 M(+15.8%) |
| Dec 2000 | -$2.99 M(+671.8%) | -$493.00 K(-58.1%) | -$2.99 M(+19.8%) |
| Sep 2000 | - | -$1.18 M(+13.1%) | -$2.50 M(+89.1%) |
| Jun 2000 | - | -$1.04 M(+270.4%) | -$1.32 M(+370.4%) |
| Mar 2000 | - | -$280.60 K | -$280.60 K |
| Dec 1999 | -$387.50 K | - | - |
FAQ
- What is Oncolytics Biotech annual EBITDA?
- What is the all time high annual EBITDA for Oncolytics Biotech?
- What is Oncolytics Biotech annual EBITDA year-on-year change?
- What is Oncolytics Biotech quarterly EBITDA?
- What is the all time high quarterly EBITDA for Oncolytics Biotech?
- What is Oncolytics Biotech quarterly EBITDA year-on-year change?
- What is Oncolytics Biotech TTM EBITDA?
- What is the all time high TTM EBITDA for Oncolytics Biotech?
- What is Oncolytics Biotech TTM EBITDA year-on-year change?
What is Oncolytics Biotech annual EBITDA?
The current annual EBITDA of ONCY is -$24.73 M
What is the all time high annual EBITDA for Oncolytics Biotech?
Oncolytics Biotech all-time high annual EBITDA is -$387.50 K
What is Oncolytics Biotech annual EBITDA year-on-year change?
Over the past year, ONCY annual EBITDA has changed by -$4.33 M (-21.25%)
What is Oncolytics Biotech quarterly EBITDA?
The current quarterly EBITDA of ONCY is -$7.18 M
What is the all time high quarterly EBITDA for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly EBITDA is -$280.60 K
What is Oncolytics Biotech quarterly EBITDA year-on-year change?
Over the past year, ONCY quarterly EBITDA has changed by +$978.60 K (+12.00%)
What is Oncolytics Biotech TTM EBITDA?
The current TTM EBITDA of ONCY is -$25.86 M
What is the all time high TTM EBITDA for Oncolytics Biotech?
Oncolytics Biotech all-time high TTM EBITDA is -$280.60 K
What is Oncolytics Biotech TTM EBITDA year-on-year change?
Over the past year, ONCY TTM EBITDA has changed by -$1.35 M (-5.52%)